Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism

American Journal of Clinical Nutrition

Volumn 98, Issue 4, 2013, Pages 895-906

  Musso, Giovanni ^a   Bo, Simona ^b   Cassader, Maurizio ^b   De Michieli, Franco ^b   Gambino, Roberto ^b  

^a GRADENIGO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FATTY ACID; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; RESISTIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIETARY INTAKE; DISEASE SEVERITY; DNA POLYMORPHISM; EDUCATION; ENDOTHELIAL DYSFUNCTION; ETHNICITY; FAMILY HISTORY; FAT TOLERANCE TEST; FATTY ACID BLOOD LEVEL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENDER; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HIGH SCHOOL; HOMEOSTASIS; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOPROTEIN METABOLISM; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PHYSICAL ACTIVITY; POPULATION RESEARCH; POSTPRANDIAL STATE; PREDICTION; PRIMARY SCHOOL; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; E-SELECTIN; ENDOTHELIUM, VASCULAR; FATTY LIVER; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; INTERCELLULAR ADHESION MOLECULE-1; LIPID METABOLISM DISORDERS; LIPOPROTEINS, LDL; LIVER; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RESISTIN; SEVERITY OF ILLNESS INDEX; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84884862443     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.113.063792     Document Type: Article

References (44)

1. Musso G, Gambino R, Cassader M, Pagano GF. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43:617-49.
2. Hamaguchi M, Kojima T, Takeda N. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143:722-8.
3. Musso G, Gambino R, Pacini G, De Michieli F, Cassader M. Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. Am J Clin Nutr 2009;89:558-67.
4. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012;55:885-904.
5. Anstee QM, Daly AK, Day CP. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochim Biophys Acta. 2011;1812: 1557-66
6. Kotronen A, Johansson LE, Johansson LM. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009;52:1056-60.
7. Xia M, Liu Y, Guo H, Wang D, Wang Y, Ling W. Retinol binding protein 4 stimulates hepatic sterol regulatory element-binding protein 1 and increases lipogenesis through the peroxisome proliferator-activated receptor-g coactivator 1b-dependent pathway. Hepatology (Epub ahead of print 8 January 2013.
8. Okazaki H, Goldstein JL, Brown MS. LXR-SREBP-1c-phospholipid transfer protein axis controls very low density lipoprotein (VLDL) particle size. J Biol Chem 2010;285:6801-10.
9. Horton JD, Shimomura I, Ikemoto S. Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. J Biol Chem 2003;278:36652-60. (Pubitemid 37139997)
10. Karasawa T, Takahashi A, Saito R. Sterol regulatory element-binding protein-1 determines plasma remnant lipoproteins and accelerates atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2011;31:1788-95.
11. Grarup N, Stender-Petersen KL, Andersson EA. Association of variants in the sterol regulatory element-binding factor 1 (SREBF1) gene with type 2 diabetes, glycemia, and insulin resistance: a study of 15,734 Danish subjects. Diabetes 2008;57:1136-42.
12. Eberlé D, Clément K, Meyre D. SREBF-1 gene polymorphisms are associated with obesity and type 2 diabetes in French obese and diabetic cohorts. Diabetes 2004;53:2153-7. (Pubitemid 38970769)
13. Harding AH, Loos RJ, Luan J, O'Rahilly S, Wareham NJ, Barroso I. Polymorphisms in the gene encoding sterol regulatory element-binding factor-1c are associated with type 2 diabetes. Diabetologia 2006;49: 2642-8. (Pubitemid 44559525)
14. Laudes M, Barroso I, Luan J, Soos MA, Yeo G, Meirhaeghe A, Logie L, Vidal-Puig A, Schafer AJ, Wareham NJ, et al. Genetic variants in human sterol regulatory element binding protein-1c in syndromes of severe insulin resistance and type 2 diabetes. Diabetes 2004;53:842-6. (Pubitemid 38270657)
15. Liu JX, Liu J, Guo Q, Liu J. Association of sterol regulatory element binding protein-1c genetic polymorphisms rs2297508 and rs11868035 with type 2 diabetes mellitus in Gansu Han and Dongxiang population. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2012;29:328-33.
16. Gambino R, Bo S, Gentile L, Musso G, Pagano G, Cavallo-Perin P, Cassader M. Transcription factor 7-like 2 (TCF7L2) polymorphism and hyperglycemia in an adult italian population-based cohort. Diabetes Care 2010;33:1233-5.
17. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, et al. Updated definitions ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
18. Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ. Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 2010;51:1577-83.
19. Miyake T, Kumagi T, Hirooka M, Koizumi M, Furukawa S, Ueda T, Tokumoto Y, Ikeda Y, Abe M, Kitai K, et al. Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a communitybased cross-sectional study. J Gastroenterol 2012;47:696-703.
20. Hernaez R, Lazo M, Bonekamp S. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011;54:1082-90.
21. Musso G, Gambino R, De Michieli F, Biroli G, Premoli A, Pagano G, Bo S, Durazzo M, Cassader M. Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. Am J Clin Nutr 2007;86:661-71. (Pubitemid 47435833)
22. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the IDF Task Force on Epidemiology and Prevention, NHLBI, AHA, WHF, IAS, and IASO. Circulation 2009;120:1640-5.
23. Pisani P, Faggiano F, Krogh V. Relative validity and reproducibility of a food frequency dietary questionnaire for use in the Italian EPIC centres. Int J Epidemiol 1997;26(suppl 1):S152-60. (Pubitemid 27129699)
24. Sacerdote C, Fiorini L, Dalmasso M. Alimentazione e rischi di cancro. Indagine su un campione di 10054 volontari residenti nell'area torinese. [Dietary habits and risk of cancer. Survey on a sample of 10054 healthy volunteers resident in the Turin area.] Turin, Italy: AGAT, 2000 (in Italian).
25. Carnovale E, Marletta P. Food composition table. Istituto Nazionale della Nutrizione. Milan, Italy: EDRA, 1997.
26. Salvini S, Parpinel M, Gnagnarella P. Banca dati di composizione degli alimenti per studi epidemiologici in Italia. [Food composition database for epidemiological studies in Italy.] Milan, Italy: Istituto Europeo di Oncologia, 1988 (in Italian).
27. Taylor HL, Jacobs DR Jr, Schucker B. Questionnaire for the assessment of leisure time physical activities. J Chronic Dis 1978;31:741-55. (Pubitemid 9140316)
28. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351:88-92. (Pubitemid 28026634)
29. Vaidya D, Szklo M, Cushman M, Holvoet P, Polak J, Bahrami H, Jenny NS, Ouyang P. Association of endothelial and oxidative stress with metabolic syndrome and subclinical atherosclerosis: multi-ethnic study of atherosclerosis. Eur J Clin Nutr 2011;65:818-25.
30. Musso G, Cassader M, Bo S, De Michieli F, Gambino R. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes 2013;62:1109-20.
31. Cobelli C, Toffolo GM, Dalla Man C. Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 2007;293:E1-15.
32. Musso G, Gambino R, Cassader M. Lipoprotein metabolism mediates the association of MTP polymorphism with beta-cell dysfunction in healthy subjects and in nondiabetic normolipidemic patients with nonalcoholic steatohepatitis. J Nutr Biochem 2010;21:834-40.
33. Musso G, Cassader M, De Michieli F, Rosina F, Orlandi F, Gambino R. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology 2012; 56:933-42.
34. O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007;100:899-904. (Pubitemid 47268287)
35. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
36. Knebel B, Haas J, Hartwig S, Jacob S, Köllmer C, Nitzgen U, Muller- Wieland D, Kotzka J. Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass. PLoS ONE 2012;7:e31812.
37. Chu X, Liu L, Na L, Lu H, Li S, Li Y, Sun C. Sterol regulatory element-binding protein-1c mediates increase of postprandial stearic acid, a potential target for improving insulin resistance, in hyperlipidemia. Diabetes 2013;62:561-71.
38. Speliotes EK, Yerges-Armstrong LM, Wu J, Hernaez R, Kim LJ, Palmer CD, Gudnason V, Eiriksdottir G, Garcia ME, Launer LJ, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 2011;7:e1001324.
39. van de Woestijne AP, Monajemi H, Kalkhoven E. Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. Obes Rev 2011;12:829-40.
40. Iwasaki Y, Iwasaki H, Yatoh S, Ishikawa M, Kato T, Matsuzaka T, Nakagawa Y, Yahagi N, Kobayashi K, Takahashi A, et al. Nuclear SREBP-1a causes loss of pancreatic beta-cells and impaired insulin secretion. Biochem Biophys Res Commun 2009;378:545-50.
41. Kato T, Shimano H, Yamamoto T. Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets. Diabetes 2008;57:2382-92.
42. Musso G, Gambino R, Cassader M. Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Annu Rev Med 2010;61: 375-92.
43. Manini TM. Energy expenditure and aging. Ageing Res Rev 2010;9:1-11.
44. Gambino R, Musso G, Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal 2011;15:1325-65.